What are the indications for Secrexizotinib?

Xalkori, also known as crizotinib, is a tyrosine kinase receptor inhibitor developed by Pfizer. It achieves the effect of treating specific types of tumors by inhibiting a variety of protein kinase targets related to the growth and spread of tumor cells.

Anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) is the main indication for crizotinib. In clinical trials, crizotinib has been proven to have significant efficacy in patients with ALK-positive NSCLC. Such patients usually present with a subtype of adenocarcinoma in non-smokers or light smokers, and the ALK gene rearranges to produce abnormal ALK proteins, leading to abnormal cell growth and spread. Crizotinib effectively controls tumor development by inhibiting the activity of this abnormal protein.

In addition to ALK-positive patients, crizotinib is also approved for the treatment of ROS1-positive advanced NSCLC patients. ROS1 is a receptor tyrosine kinase related to cell growth and differentiation. Its gene mutation or fusion can lead to abnormal proliferation of tumor cells. Crizotinib can also achieve the effect of treating this type of tumor by inhibiting the activity of ROS1.

The therapeutic effect of crizotinib is closely related to the patient's genetic test results. Therefore, before using crizotinib, patients must undergo precise genetic testing to determine whether they have the above-mentioned genetic mutations related to drug sensitivity.

Although crizotinib has shown significant efficacy in the above indications, it may also cause some adverse reactions, such as blurred vision, nausea, vomiting, diarrhea, etc. Therefore, it is necessary to pay close attention to the patient's response during use and adjust the treatment plan in a timely manner according to the situation.